Latest News and Press Releases

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous...

Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug...

CONNECTA Therapeutics initiates Phase IIa trial advancing treatments for rare CNS disorders, strengthening its clinical pipeline and development strategy.

NOON WORLD, the cognitive wellness brand redefining the functional gummy category, is now available in 878 Target stores nationwide.

Omniscient (o8t®) secures $27.2M Series D funding to scale its AI-powered Quicktome® brain mapping platform and accelerate personalized brain care globally

SYDNEY, May 28, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) today announces the successful outcome of its scheduled scientific advice meeting (written response) on Alzheimer’s...

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population

CNS CEO David Harrington joins the Brain to Brain podcast to discuss brain injury recovery, advocacy and why it is never too late to pursue rehabilitation.

Denovo Announces Issuance of U.S. Patent of Novel Genetic Biomarker ANK3 (DGM4™) for Liafensine (DB104)

If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma...